Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Todisco JosephOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:13,561Price:$3.74
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Lefkowitz Steven WOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Stewart Robert AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Kaplan MyronOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Dillione JanetOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Dunton Alan WOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Duncan Gregory ScottOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,603Price:$3.47
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
Filings by filing date
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Lefkowitz Steven WOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Stewart Robert AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Kaplan MyronOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Dillione JanetOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Dunton Alan WOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 05, 2024 (filed on Mar 20, 2024)Insider Name:Duncan Gregory ScottOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Todisco JosephOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:13,561Price:$3.74
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,603Price:$3.47
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Masson-Hurlburt ElizabethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:50,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 300 Connell Drive, Suite 4200 BERKELEY HEIGHTS NJ 07922 |
Tel: | 1-617-4307576 |
Website: | https://cormedix.com |
IR: | See website |
Key People | ||
Joseph Todisco Chief Executive Officer, Director | Matthew T. David Chief Financial Officer, Executive Vice President | Elizabeth Massonhurlburt Executive Vice President, Head of Clinical and Medical Affairs |
Erin Mistry Executive Vice President, Chief Commercial Officer | Phoebe Mounts Executive Vice President |
Business Overview |
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors. |
Financial Overview |
For the fiscal year ended 31 December 2023, CorMedix Inc revenues decreased from $65K to $0K. Net loss increased 56% to $46.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling, general and administrative increase of 79% to $35.8M (expense), Research and development increase of 23% to $13.2M (expense). |
Employees: | 82 as of Mar 7, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $221.97M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$48.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$46.34M as of Dec 31, 2023 |
Free cash flow (TTM): | -$38.74M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 54,981,102 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |